menu

Real-World Scenarios in Uterine Fibroids and Endometriosis: Diagnosis, Assessment, & the Role of GnRH Antagonists

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Real-World Scenarios in Uterine Fibroids and Endometriosis: Diagnosis, Assessment, and the Role of GnRH Antagonists

0.75 credits
45 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Related
Comments
  • Overview

    Uterine fibroids and endometriosis are common gynecologic diseases that often cause pain, distress, and decreased quality of life. Unfortunately, they are often dismissed by clinicians as minor conditions. Traditional treatment options have included surgery, hormone therapy, radiation, and medical therapies. But now, gonadotropin-releasing hormone (GnRH) antagonists are proving to be an effective and well-tolerated alternative to invasive procedures. This real-world simulation reviews these emerging therapies and approaches for aligning patient priorities and desires with individualized treatment options. 

  • Disclosure of Conflicts of Interest

    The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been mitigated through an established COI mitigation process and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.

    Erin T. Carey, MD, MSCR
    Receipt of intellectual property right/patent holder: Patent applications for vestibulodynia and myofascial pelvic pain through UNC
    Other: Served as an expert witness for pelvic pain and surgical complications

    Erica E. Marsh, MD, MSCI, FACOG
    Consulting fees/advisory boards: Myovant Sciences Ltd, Pfizer Inc

    The peer reviewers and activity planners have no financial relationships to disclose.

  • Target Audience

    This activity is intended for obstetrician-gynecologists, primary care physicians, nurse practitioners, physician assistants, and nurses involved in the care and treatment of patients with uterine fibroids and/or endometriosis.

  • Learning Objectives

    Upon completion, participants should be able to:

    • Recognize the signs, symptoms, patient characteristics, and comorbidities that are associated with UF and endometriosis
    • Evaluate the benefits and limitations of available treatments and the utility of current guidance for the management of UF and endometriosis
    • Integrate the current evidence surrounding GnRH antagonists into individualized management plans for patients with UF or endometriosis
    • Incorporate patient preferences and shared decision making into personalized treatment plans for patients with UF or endometriosis
  • Accreditation and Credit Designation Statements

    Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Med-IQ designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Med-IQ is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

    This nursing activity has been approved for up to 0.75 contact hour.

  • Disclaimer

    The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition. 

  • Provider(s)/Educational Partner(s)

    Provided by Med-IQ.

  • Commercial Support

    This activity is supported by an educational grant from Pfizer Inc and Myovant Sciences Ltd.

  • Disclosure Policy

    Med-IQ requires any person in a position to control the content of an educational activity to disclose all financial relationships with any ineligible company over the past 24 months. The ACCME deems financial relationships as relevant if the educational content an individual can control is related to the business lines or products of the ineligible company. Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and mitigate COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration. 

  • Activity Planners

    Jessica Kimball, CST, MBA
    Clinical Learning Strategist

    Sara Samuel, MSc, MPhil, MS
    Clinical Content Manager
    Med-IQ
    Baltimore, MD

    Larissa Picard-Broussard
    CME Coordinator
    Med-IQ
    Baltimore, MD

    Nikki Berry
    Director, Accreditation
    Med-IQ
    Baltimore, MD

    Kathryn Schaefer, MSN, RN, CPHRM
    Associate Director, Education Quality and Compliance
    Med-IQ
    East Lansing, MI

  • Medium/Method of Participation

    This is a 0.75-credit CME/CE activity. To receive credit, read the introductory CME/CE material, complete all of the modules, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

    Initial Release Date: October 18, 2022
    Expiration Date: October 17, 2023
    Estimated Time to Complete This Activity: 45 minutes

  • Drug/Product usage by Faculty

    Off-label/unapproved drug uses or products are mentioned within this activity.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Uterine fibroids and endometriosis are common gynecologic diseases that often cause pain, distress, and decreased quality of life. Unfortunately, they are often dismissed by clinicians as minor conditions. Traditional treatment options have included surgery, hormone therapy, radiation, and medical therapies. But now, gonadotropin-releasing hormone (GnRH) antagonists are proving to be an effective and well-tolerated alternative to invasive procedures. This real-world simulation reviews these emerging therapies and approaches for aligning patient priorities and desires with individualized treatment options. 

  • Disclosure of Conflicts of Interest

    The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been mitigated through an established COI mitigation process and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.

    Erin T. Carey, MD, MSCR
    Receipt of intellectual property right/patent holder: Patent applications for vestibulodynia and myofascial pelvic pain through UNC
    Other: Served as an expert witness for pelvic pain and surgical complications

    Erica E. Marsh, MD, MSCI, FACOG
    Consulting fees/advisory boards: Myovant Sciences Ltd, Pfizer Inc

    The peer reviewers and activity planners have no financial relationships to disclose.

  • Target Audience

    This activity is intended for obstetrician-gynecologists, primary care physicians, nurse practitioners, physician assistants, and nurses involved in the care and treatment of patients with uterine fibroids and/or endometriosis.

  • Learning Objectives

    Upon completion, participants should be able to:

    • Recognize the signs, symptoms, patient characteristics, and comorbidities that are associated with UF and endometriosis
    • Evaluate the benefits and limitations of available treatments and the utility of current guidance for the management of UF and endometriosis
    • Integrate the current evidence surrounding GnRH antagonists into individualized management plans for patients with UF or endometriosis
    • Incorporate patient preferences and shared decision making into personalized treatment plans for patients with UF or endometriosis
  • Accreditation and Credit Designation Statements

    Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Med-IQ designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Med-IQ is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

    This nursing activity has been approved for up to 0.75 contact hour.

  • Disclaimer

    The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition. 

  • Provider(s)/Educational Partner(s)

    Provided by Med-IQ.

  • Commercial Support

    This activity is supported by an educational grant from Pfizer Inc and Myovant Sciences Ltd.

  • Disclosure Policy

    Med-IQ requires any person in a position to control the content of an educational activity to disclose all financial relationships with any ineligible company over the past 24 months. The ACCME deems financial relationships as relevant if the educational content an individual can control is related to the business lines or products of the ineligible company. Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and mitigate COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration. 

  • Activity Planners

    Jessica Kimball, CST, MBA
    Clinical Learning Strategist

    Sara Samuel, MSc, MPhil, MS
    Clinical Content Manager
    Med-IQ
    Baltimore, MD

    Larissa Picard-Broussard
    CME Coordinator
    Med-IQ
    Baltimore, MD

    Nikki Berry
    Director, Accreditation
    Med-IQ
    Baltimore, MD

    Kathryn Schaefer, MSN, RN, CPHRM
    Associate Director, Education Quality and Compliance
    Med-IQ
    East Lansing, MI

  • Medium/Method of Participation

    This is a 0.75-credit CME/CE activity. To receive credit, read the introductory CME/CE material, complete all of the modules, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

    Initial Release Date: October 18, 2022
    Expiration Date: October 17, 2023
    Estimated Time to Complete This Activity: 45 minutes

  • Drug/Product usage by Faculty

    Off-label/unapproved drug uses or products are mentioned within this activity.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule7 Dec 2022